Radioimmunotherapy with alpha-emitting nuclides.
This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promising alpha-emitting isotopes available for human clinical use. The selective cytotoxicity offered by alpha particle-emitting radioimmunoconstructs is due to the high linear energy transfer and short particle path length of these radionuclides. Based upon the pharmacokinetics of alpha particle-emitting radioimmunoconstructs, both stochastic and conventional dosimetric methodology is discussed, as is the preclinical and initial clinical use of these radionuclides conjugated to monoclonal antibodies for the treatment of human neoplasia.
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
M R
MR
McDevitt
G
G
Sgouros
R D
RD
Finn
J L
JL
Humm
J G
JG
Jurcic
S M
SM
Larson
D A
DA
Scheinberg
D000512:Alpha Particles / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D011879:Radiotherapy Dosage
D011868:Radioisotopes